These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 11208833)

  • 1. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    Spaepen K; Stroobants S; Dupont P; Thomas J; Vandenberghe P; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Br J Haematol; 2001 Nov; 115(2):272-8. PubMed ID: 11703321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J; Qiao W; Wang C; Wang T; Xing Y
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
    J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.
    Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Maertens J; Bormans G; Thomas J; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Blood; 2003 Jul; 102(1):53-9. PubMed ID: 12609836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
    de Wit M; Bumann D; Beyer W; Herbst K; Clausen M; Hossfeld DK
    Ann Oncol; 1997; 8 Suppl 1():57-60. PubMed ID: 9187431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up.
    Amthauer H; Furth C; Denecke T; Hundsdoerfer P; Voelker T; Seeger K; Stöver B; Henze G
    Klin Padiatr; 2005; 217(6):327-33. PubMed ID: 16307418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
    Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
    Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
    J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
    Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
    Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.